enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Amgen aims to treat liver, kidney diseases with obesity drug

    www.aol.com/news/amgen-aims-treat-liver-kidney...

    (Reuters) -Amgen will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert ...

  3. US FDA approves Amgen drug for small cell lung cancer - AOL

    www.aol.com/news/us-fda-approves-amgen-drug...

    The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...

  4. Amgen's muscular disorder drug meets main goal in late-stage ...

    www.aol.com/news/amgens-muscular-disorder-drug...

    (Reuters) -Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease, meeting the main goal of ...

  5. Analysis-Wall Street awaits Amgen weight-loss drug data ... - AOL

    www.aol.com/analysis-wall-street-awaits-amgen...

    Amgen shares closed at $287.87 on Wednesday, down about 9% from earlier this month, when analysts at Cantor Fitzgerald said their review of Phase 1 MariTide data showed a drop in bone mineral ...

  6. Amgen - Wikipedia

    en.wikipedia.org/wiki/Amgen

    AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]

  7. US FDA approves Amgen's biosimilar to AstraZeneca's rare ...

    www.aol.com/news/us-fda-approves-amgens-bio...

    Amgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex biological drugs. In 2022, the company said that Bkemv met the main goal of a late stage study, where ...

  8. Erenumab - Wikipedia

    en.wikipedia.org/wiki/Erenumab

    Erenumab was developed by Amgen Inc. in conjunction with Novartis. [5] In the phase III STRIVE clinical trial 955 patients were divided into three groups in a 1:1:1 ratio. Each group was injected subcutaneously monthly with 0, 70 or 140 mg erenumab over a period of 6 months. The results were measured as mean monthly migraine days in months 4, 5 ...

  9. Amgen's peek at its GLP-1 drug trial results heightens ... - AOL

    www.aol.com/finance/amgens-peek-glp-1-drug...

    Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.CEO Bob Bradway shared a peek at phase II results of the ...